 Many c-Met inhibitors are currently in clinical trials.Crizotinib and Cabozantinib were the first to be approved by the U.S. FDA; Crizotinib received accelerated approval for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by a test approved by the U.S. Food and Drug Administration (FDA).Cabozantinib was approved in November 2012 for the treatment of medullary thyroid cancer and it has also started clinical trials for the treatment of prostate, bladder, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, hepatocellular and kidney cancers.